RSLS +500% upside potential according to this analyst RSLS, ReShape Lifesciences, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.
On 11/12/2021 Anthony Vendetti from Maxim Group brokerage Reiterated the Buy Rating for RSLS with a price target of $8.00.
That is more that 5X from the current price.
Looking forward to read your opinion about it.
Reshape
RSLS ReShape Lifesciences Price Target- ReShape leader in weight loss market
- FDA approved Lap-Band manufacturing moved to the US
- eliminated debt overhang
- ReShape Marketplace - digital health solution
June 30, 2021: Cash and cash equivalents and restricted cash were $40.2 million.
ReShape Market Cap only 50.061M
Shares Outstanding 17.20M
On 7/1/2021, Ben Haynor from Alliance Global Partners brokerage Lowered the Price Target from $18.50 to $13.75
My price target is the 9.6usd resistance.
I`m looking forward to read your opinion about RSLS.
RSLS ReShape Lifesciences Global Weight-Loss Leader | $ TargetOn 6/17/2021 Alliance Global Partners brokerage Boosted the Price Target for RSLS ReShape Lifesciences stock from $12.00 to $18.50!
ReShape Lifesciences is America's premier weight-loss solutions company.
The FDA-approved Lap-Band® program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy.
The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. Reshapecare™ virtual health coaching program is a virtual telehealth weight management program that supports lifestyle changes for all weight-loss patients, to help them keep the weight off over time. (accesswire.com)
My price target is 12usd short term.